CAR-T vs. bispecific therapies: Two growth stories are reshaping hematologic oncology
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Developing and launching a successful cell and gene therapy requires specialist expertise and out-of-the-box thinking to adapt to new business models and pricing strategies. CRA has significant experience in this space and understands the unique challenges that gene or cell therapies can bring to manufacturers and the healthcare industry. We bring industry-leading methodologies from clinical development through launch to support commercial, medical affairs, pricing, market access, and policy makers/regulators in navigating a rapidly evolving landscape.
CRA’s experience stems from more than 100 gene therapy engagements across multiple therapeutic areas.
While both CAR-T cell therapies and bispecific antibodies have experienced rapid growth in recent years, new analysis by CRA’s Chris Nüesch suggests that the...
Advances in neuroscience are reshaping our understanding of the brain and opening new frontiers in how we diagnose, treat, and ultimately prevent neurological...